Single dose phenytoin clearance during erythromycin treatment

Area of Science:

• Pharmacology
• Drug Interactions
• Clinical Kinetics

Background:

• Phenytoin (PHT) is an antiepileptic drug with a narrow therapeutic index.
• Erythromycin is a commonly prescribed antibiotic that can interact with other medications.
• Understanding drug interactions is crucial for patient safety and effective treatment.

Purpose of the Study:

• To investigate the effect of erythromycin on the single-dose pharmacokinetics of phenytoin in healthy male volunteers.
• To determine if erythromycin alters phenytoin clearance, volume of distribution, or half-life.

Main Methods:

• A crossover study design was employed with eight healthy male volunteers.
• Phenytoin (300 mg, oral) was administered alone and after a 7-day erythromycin regimen (333 mg orally every 8 hours).
• Plasma concentrations of phenytoin were measured over 48 hours; saliva concentrations were measured at 48 hours.

Main Results:

• Erythromycin treatment did not significantly change the mean values for phenytoin intrinsic clearance (CLint/F), volume of distribution (V/F), or half-life (t 1/2).
• Estimates of intrinsic unbound PHT clearance (CL'int/F) also showed no significant difference between control and erythromycin phases.
• A good correlation was observed between CL'int/F calculated from CLint/F and that derived from salivary data.

Conclusions:

• Erythromycin does not significantly affect the single-dose pharmacokinetics of phenytoin in healthy individuals.
• Despite no significant group effect, individual variability in PHT clearance during erythromycin co-administration warrants close patient monitoring.
• This study highlights the importance of considering potential drug interactions even when population-level data show no significant effect.